胃と腸43巻9号

2008年08月発行

今月の主題 colitic cancer/dysplasiaの早期診断─病理組織診断の問題点も含めて 主題

欧米におけるcolitic cancer/dysplasiaの診断・治療―現状と問題点

著者： 平田一郎¹

所属機関： ¹藤田保健衛生大学消化管内科

ページ範囲：P.1273 - P.1280

要旨　colitic cancer/dysplasiaの診断と治療の現状と問題点に関する欧米の文献をレビューし総説した．挙げられる問題点は，（1）サーベイランスプログラムが各ガイドラインで異なっている，（2）サーベイランスにおいてガイドラインが提唱する生検個数が遵守されていない，（3）各サーベイランスの有効性を立証する直接的証拠が示されていない，（4）INDとLGDの診断において診断者間でかなりの不一致がみられる，（5）平坦型LGDの取り扱いに関して統一見解が得られていない，（6）DALMの定義に解釈のずれがある，（7）DALMとALM/ALD，散発性腺腫，炎症性ポリープの鑑別が難しい例があり，適切な鑑別方法が見い出されていない，などである．

参考文献

1）Warren S, Sommers SC. Pathogenesis of ulcerative colitis. Am J Pathol 25:657-679, 1949

2）Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease:standardized classification with provisional clinical applications. Hum Pathol 14:931-968, 1983

3）Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. a critical review. N Engl J Med 316:1654-1658, 1987

4）Itzkowitz SH, Present DH. Consensus conference:colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11:314-321, 2005

5）Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel disease. Gastroenterology 126:1634-1648, 2004

6）Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125:1311-1319, 2003

7）Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107:934-944, 1994

8）Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis:comparison with clinical outcome. Hum Pathol 20:1008-1014, 1989

9）Rubin DT, Kavitt RT. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am 35:581-604, 2006

10）Dixon MF, Brown LJ, Gilmour HM, et al. Observer variation in the assessment of dysplasia of ulcerative colitis. Histopathology 13:385-398, 1988

11）Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103:1611-1620, 1992

12）Itzkowtiz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease:the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7-G17, 2004

13）Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults（update）:American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99:1371-1385, 2004

14）Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51:10-12, 2002

15）Bernstein CN, Weinstein WM, Levine DS, et al. Physicians'perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 90:2106-2114, 1995

16）Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis:an analysis of performance. Gastrointest Endosc 51:123-128, 2000

17）Ahmadi AA, Polyak S. Endoscopy/surveillance in inflammatory bowel disease. Surg Clin North Am 87:743-762, 2007

18）Rubin DT, Turner JR. Surveillance of dysplasia in inflammatory bowel disease:The gastroenterologist-pathologist partnership. Clin Gastroenterol Hepatol 4:1309-1313, 2006

19）Lindberg B, Perrson B, Veress B, et al. Twenty years'colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand J Gastroenterol 31:1195-1204, 1996

20）Ullman TA, Loftus EV Jr, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 97:922-927, 2002

21）Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?Lancet 343:71-74, 1994

22）Taylor BA, Pemberton JH, Carpenter HA, et al. Dysplasia in chronic ulcerative colitis:implications for colonoscopic surveillance. Dis Colon Rectum 35:950-956, 1992

23）Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130:1030-1038, 2006

24）Lim CH, Dixon MF, Vail A, et al. Ten-year follow-up of ulcerative colitis patients with and without low grade dysplasia. Gut 52:1127-1132, 2003

25）Befrits R, Ljung T, Jaramillo E, et al. Low grade dysplasia in extensive long standing inflammatory bowel disease:a follow up study. Dis Colon Rectum 45:615-620, 2002

26）Rodriguez SA, Collins JM, Knigge KL, et al. Surveillance and management of dysplasia in ulcerative colitis. Gastrointest Endosc 65:432-439, 2007

27）Blackstone MO, Riddell RH, Rogers BH, et al. Dysplasia-associated lesion or mass（DALM）detected by colonoscopy in long-standing ulcerative colitis:an indication for colectomy. Gastroenterology 80:366-374, 1981

28）Mitchell PJ, Salmo E, Haboubi NY. Inflammatory bowel disease:the problems of dysplasia and surveillance. Tech Coloproctol 11:299-309, 2007

29）Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 60:334-339, 2004

30）Ludeman L, Shepherd NA. Problem areas in the pathology of chronic inflammatory bowel disease. Curr Diagn Pathol 12:248-260, 2006

31）Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2:534-541,2004

32）Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis:conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 117:1295-1300, 1999

33）Farraye FA, Waye JD, Moscandrew M, et al. Variability in the diagnosis and management of adenoma-like and non-adenoma-like dysplasia-associated lesions or masses in inflammatory bowel disease:an internet based study. Gastrointest Endosc 66:519-529, 2007

34）Rutter M, Saunders B, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis:endoscopic appearances help predict cancer risk. Gut 53:1813-1816, 2004

35）Goldman JR. The histologic diagnosis of dysplasia, dysplasia associated lesion or mass, and adenoma. A pathologists'perspective. J Clin Gastroenterol 36:S63-S69, 2003

36）Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in inflammatory bowel disease:a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. Am J Surg Pathol 22:275-284, 1998

37）Löfberg R, Broström O, Karlén P, et al. Colonoscopic surveillance in long-standing total ulcerative colitis─a 15-year follow-up study. Gastroenterology 99:1021-1031, 1990

38）Rozen P, Baratz M, Ferer F, et al. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology 108:1361-1370, 1995

39）Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis:historical cohort study. Am J Gastroenterol 85:1083-1087, 1990

40）Choi PM, Nugent FW, Schoetz DJ, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 105:418-424, 1993

41）Karlén P, Kornfeld D, Broström O, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis?A population based case control study. Gut 42:711-714, 1998

42）Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 19:CD000279, 2006

43）Provenzale D, Wong JB, Onken JE, et al. Performing a cost-effectiveness analysis:surveillance of patients with ulcerative colitis. Am J Gastroenterol 93:872-880,1998

44）Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 53:V1-V16, 2004

45）Chambers WM, Warren BF, Jewell DP, et al. Cancer surveillance in ulcerative colitis. Br J Surg 92:928-936, 2005

46）Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 89:1342-1346, 1985

47）Lennard-Jones JE, Melville DM, Morson BC, et al. Precancer and cancer in extensive ulcerative colitis:findings among 401 patients over 22 years. Gut 31:800-806, 1990

48）Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 53:256-260, 2004

49）Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124:880-888, 2003

50）Chen R, Rabinovitch PS, Crispin DA, et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 162:665-672, 2003

51）Rabinovitch PS, Dziadon S, Brentnall TA, et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 59:5148-5153, 1999

52）Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61:3573-3577, 2001

53）Selaru FM, Xu Y, Yin J, et al. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology 122:606-613, 2002